Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5619552 | 0.85 | KDM4D (0.44) | KMT2A | |
| SCHEMBL5618651 | 0.85 | KMT2A (0.47) | KMT2ACACNA1BUTS2RDRD2MAPK1 | |
| SCHEMBL5619497 | 0.83 | KMT2A (0.39) | KMT2AMAPK1CTSK | |
| SCHEMBL5620010 | 0.83 | KDM4D (0.40) | CACNA1BUTS2RDRD2CTSK | |
| SCHEMBL5619494 | 0.83 | KMT2A (0.39) | KMT2AMAPK1CTSK | |
| SCHEMBL5619154 | 0.82 | ADORA2B (0.39) | KMT2AMAPK1CTSK | |
| SCHEMBL5618387 | 0.80 | CTSK (0.37) | KMT2AMAPK1CTSK | |
| SCHEMBL5618694 | 0.80 | CTSK (0.37) | KMT2AMAPK1CTSK | |
| SCHEMBL4712368 | 0.74 | KMT2A (0.53) | KMT2AMAPK1CTSK | |
| SCHEMBL4712370 | 0.74 | KMT2A (0.53) | KMT2AMAPK1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186843-B2 | potent antibacterial activity against various bacteria including drug-resistant strains | DAIICHI PHARMACEUTICAL CO. LTD. (JP) | 2007-03-06 | — | — | US | disclosed |
| US-20040209940-A1 | Aminomethylpyrrolidine derivatives having aromatic substituents | DAIICHI PHARMACEUTICAL CO., LTD. | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209940-A1 | Aminomethylpyrrolidine derivatives having aromatic substituents | Q6ZSR9, NAT1, NAT10 | KMT2A 630/4885CACNA1B 985/4885UTS2R 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.